Fig. 1From: Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective reviewAll types and the number of immune checkpoint inhibitors (ICIs). Nivolumab was the most commonly used ICI, followed by pembrolizumab and atezolizumab. Forty-three patients experienced a change in the type of ICI they were administered, and three patients received dual ICI therapyBack to article page